SMAD4 Germline Mutation Analysis
The SMAD4 genes mediate the biological effects of the Transforming Growth Factor-ß (TGF-ß) superfamily located on the surface of epithelial cells. TGF-ß serves as a differential factor whose pathway normally inhibits growth and proliferation and promotes cell differentiation. The SMAD4 gene is located on the long (q) arm of chromosome 18. It encodes a cytoplasmic mediator that transduces the TGF-ß signal from the cell membrane to the nucleus by forming complexes with other SMAD proteins. In the nucleus, the SMAD protein complex binds to specific areas of DNA where it controls the activity of particular genes and regulates cell growth and division (proliferation). By controlling gene activity and regulating cell proliferation, the SMAD4 protein serves both as a transcription factor and as a tumor suppressor that regulates cell proliferation and differentiation. SMAD4 gene mutations affect the signaling pathway of TGF-ß proteins. Disruption of this pathway may interfere with both the tumor suppressor function of the SMAD4 protein and the appropriate development of the boundaries between veins and arteries, resulting in the signs and symptoms of juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome.
More than 60 mutations in the SMAD4 gene have been found to cause juvenile polyposis syndrome. One mutation that has been found in multiple affected individuals deletes four DNA building blocks (nucleotides) in a region of the SMAD4 gene called exon 9 (written as 1244_1247delACAG). This mutation is thought to cause a more aggressive form of juvenile polyposis syndrome characterized by numerous polyps throughout the gastrointestinal tract and a greater risk for cancer development.
Juvenile Polyposis Syndrome (JPS) is a rare autosomal dominant inherited hamartomatous polyposis syndrome with increased susceptibility to colorectal cancer. Clinical diagnosis of JPS is typically made when one of the following criteria is met: more than five juvenile polyps in the colorectum; multiple juvenile polyps throughout the GI tract; or any number of juvenile polyps and a family history of gastrointestinal polyps. Juvenile refers to the developmentally immature nature of the polyp, not the age of disease onset. In addition to polyposis, 10-20% of JPS patients also have extracolonic abnormalities such as congenital heart defects, cleft lip or palate, microcephaly, and malrotations. Although a solitary juvenile polyp in the general population has very little malignant potential, patients with JPS have a 68% chance of developing gastrointestinal cancer by the age of 60. Thus, confirming a diagnosis of JPS is important for the appropriate surveillance and management of patients with juvenile polyps.
Hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu disease) is an autosomal dominant disorder of blood vessel formation affecting 1/8000 -1/ 10,000 people also associated with genes that mediate biological function of TGF beta signaling including endoglin (ENG), activin receptor-like kinases 1 (ALK1) and SMAD4. Abnormal direct connections of arteries and veins in larger vessels manifest as arteriovenous malformations (AVMs) most often in the lungs, liver, and brain. Smaller vessel abnormalities result in telangiectases, especially on the face, hands, and mucous membranes. The most common and often first symptom is recurrent epistaxis (nosebleeds) beginning in early adolescence. Gastrointestinal bleeding due to intestinal telangiectasias is common in patients over 40, and like epistaxis, it can become a significant medical concern. The age of onset and severity of symptoms vary widely. HHT is treated symptomatically and managed through surveillance for AVMs and preventive care.
In addition to SMAD4 mutation, other genes associated with HHT also function in TGF-beta signaling. Mutations in the endoglin gene (ENG) cause HHT type 1, which has a high prevalence of pulmonary AVMs. Mutations in the activin receptor-like kinase 1 gene (ACVRL1 or ALK1) cause HHT type 2, which causes fewer pulmonary and cerebral AVMs than type 1 but more hepatic AVMs. Each of these two genes is responsible for approximately 30-40% of HHT cases. Full gene sequence analyses with gross deletion/duplication testing of both genes detects mutations in 80-85% of patients. The SMAD4 gene accounts for 2-3% of cases of HHT and adds juvenile polyposis to the phenotype in most cases.
People with mutations in the SMAD4 gene appear to have an increased risk of developing various cancers. Some of these gene mutations are inherited, while others are acquired during a person's lifetime. Such acquired (somatic) mutations are present only in certain cells. Cells with mutations in the SMAD4 gene, whether inherited or somatic, may proliferate out of control and result in a tumor, often in the colon or pancreas. This test is mainly used for clinical diagnosis of JPS or AVMs. This test is specifically designed to detect germline mutations and should not be used for the detection of somatic mutations in cancers and tumors.
- Diagnosis of Juvenile Polyposis Syndrome
- Aid in diagnosis of hereditary hemorrhagic telangiectasia
- Confirmation of diagnosis in symptomatic individuals
- Determination of disease status in at-risk family members
- Disease management and life improvement (minimize complications)
Clinical diagnosis of JPS is typically made when one of the following criteria is met: more than five juvenile polyps in the colorectum; multiple juvenile polyps throughout the GI tract; or any number of juvenile polyps and a family history of gastrointestinal polyps (Chow & Macrae. J Gastroenterol Hepatol. 2005; 20:1634-1640).
Approximately 80 pathogenic mutations have been identified throughout the SMAD4 gene, and most (~95%) are of the type (e.g. single nucleotide, small insertions or deletions) that can be detected by DNA sequencing; 2-10% can be detected by Del/Dup analysis. This test is predicted to identify a SMAD4 mutation in ~20% of patients diagnosed with JPS (Calva-Cerqueira et al. Clin Genet. 2009; 75:79-85).
A positive result means a pathogenic gene mutation predicted to cause JPS, JP/HHT syndrome, or HHT was detected. A negative result does not rule out JPS, JP/HHT, or HHT due to the possibility of an undetectable SMAD4 or a mutation in another causative gene(s) not tested.
An uncertain result means that a DNA variant was detected, but it is not known whether this variant is benign or pathogenic. Medical management should rely on clinical findings and family history.
Negative for mutations analyzed (No mutations detected)
Buccal Brushes, Saliva, whole blood collected in purple top tubes (EDTA), Chorionic Villus Sampling (CVS), Amniocentesis or amniotic fluid.
Blood: A single tube with 1-5 mL whole blood in EDTA (1-2mL for infants). Ship overnight at ambient temperature. Specimen is stable for 7 days if stored at refrigeration.
Buccal Brushes: Buccal cells can be collected by brushing the check wall and stored and transported in special transport medium (lab dependent).
Amniotic fluid and CVS: Collect minimum 10 mL amniotic fluid or collect minimum 5 mg CVS, or 2 T25 flasks of cultured villi or amniocytes. Ship overnight at ambient temperature (lab dependent).
Stability (blood)
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- J Gastroenterol Hepatol. 2005 Nov;20(11):1634-40. [PMID: 16246179]
- World J Gastroenterol. 2011 Nov 28;17(44):4839-44. [PMID: 22171123]
- Ann Surg Oncol. 2011 Dec;18(13):3694-700 [PMID: 21347779]
- JAMA. 2005 Nov 16;294(19):2465-73. [PMID: 16287957]
- Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):44-55. [PMID: 15264272]
- Cells Tissues Organs. 2007;185(1-3):123-30. [PMID: 17587818]